BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Mr. Neil Kumar, PhD$5B
Market Cap • 25/07/20242019
(há 5 anos)
2019
(5 years ago)
NASDAQ
Listagem
Palo Alto
Sede • California396
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
BBIOSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.